Calcified Tissue International

, Volume 75, Issue 2, pp 123–132 | Cite as

Two Single Nucleotide Polymorphisms in the CYP17 and COMT Genes—Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women with or without Hormone Replacement Therapy

The Danish Osteoporosis Prevention Study
  • C. L. Tofteng
  • B. Abrahamsen
  • J. E. B. Jensen
  • S. Petersen
  • J. Teilmann
  • A. Kindmark
  • P. Vestergaard
  • J. Gram
  • B. L. Langdahl
  • L. Mosekilde
Article

Abstract

Sex steroids are important physiologic regulators of bone mass, and genes regulating sex steroid production and metabolism are obvious as candidate genes for osteoporosis susceptibility. We present data from a study of 1795 recent postmenopausal women, assigned to either hormone replacement therapy (HRT) or no treatment and followed for 5 years. The association between bone mass measurements and two single nucleotide polymorphisms, a T (A1) to C (A2) transition in the 5′-UTR of the cytochrome P450c17α (CYP17) gene and a G (Val) to A (Met) transition in exon 4 of the catechol-O-methyltransferase (COMT) gene, was evaluated. Association with CYP17 genotype was modified by body mass index (BMI). In lean women, individuals homozygous for the CYP17 A2 allele were 1 cm shorter and had lower baseline BMD (bone mineral density), BMC, and CSA (cross sectional area) in the spine and femoral neck than did other women (BMD spine A2A2: 0.975 g/cm2 versus 1.011 g/cm2 in A1A1 + A1A2, P = 0.002). Conversely, an adverse association with A2A2 and bone loss over 5 years seemed present only in overweight women, but differences were small. Response to HRT was not dependent on CYP17 genotype. COMT genotype was not associated with bone mass at baseline, bone loss in untreated women, or response to HRT. In conclusion, the A2 allele of the CYP17 T27-C polymorphism is associated with reduced bone mass and bone size in lean perimenopausal women, whereas high BMI protects against this negative association. The COMT G1947-A polymorphism is not associated with bone parameters in this study.

Keywords

Bone mineral density Genetics CYP17 COMT Body mass index 

Notes

Acknowledgments

The authors are grateful to all technicians and secretarial staff, who contributed to the study. Birgit Svenstrup, The State Serum Institute, is acknowledged for assistance and advice regarding SHBG and sex steroid analyses. The DOPS is a collaborative study with participation of the osteoporosis research clinics at Aarhus University Hospital, Odense University Hospital, Hilleroed Central Hospital and Hvidovre Hospital. The DOPS is financially supported by grants from the Karen Elise Jensen Foundation, Denmark, and from Novo Nordisk Farmaka (Lyngby, Denmark). This study was supported by research grants from Th. Maigaards Eftf. Fru Lily Benthine Lunds Fond af 01.06.78, Grosserer Knud Hecht-Nielsen og hustru Gerda Hecht-Nielsens legat, and Eli Lilly Denmark.

References

  1. 1.
    Riggs, BL, Khosla, S, Melton, LJ,III 2002Sex steroids and the construction and conservation of the adult skeletonEndocr Rev23279302CrossRefPubMedGoogle Scholar
  2. 2.
    Fan, YS, Sasi, R, Lee, C, Winter, JS, Waterman, MR, Lin, CC 1992Localization of the human CYP17 gene (cytochrome P450(17 alpha)) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome bandingGenomics1411101111PubMedGoogle Scholar
  3. 3.
    Picado-Leonard, J, Miller, WL 1987Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21DNA6439448PubMedGoogle Scholar
  4. 4.
    Carey, AH, Waterworth, D, Patel, K, White, D, Little, J, Novelli, P, Franks, S, Williamson, R 1994Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17Hum Mol Genet318731876PubMedGoogle Scholar
  5. 5.
    Zmuda, JM, Cauley, JA, Kuller, LH, Ferrell, RE 2001A common promoter variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in menJ Bone Miner Res16911917PubMedGoogle Scholar
  6. 6.
    Nedelcheva, KV, Haraldsen, EK, Anderson, KB, Lonning, PE, Erikstein, B, Karesen, R, Gabrielsen, OS, Borresen-Dale, AL 1999CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1Cancer Res5928252828PubMedGoogle Scholar
  7. 7.
    Lin, CJ, Martens, JW, Miller, WL 2001NF-1C, Sp1, and Sp3 are essential for transcription of the human gene for P450c17 (steroid 17alpha-hydroxylase/17,20 lyase) in human adrenal NCI-H295A cellsMol Endocrinol1512771293CrossRefPubMedGoogle Scholar
  8. 8.
    Zhu, BT, Conney, AH 1998Functional role of estrogen metabolism in target cells: review and perspectivesCarcinogenesis19127CrossRefPubMedGoogle Scholar
  9. 9.
    Winqvist, R, Lundstrom, K, Salminen, M, Laatikainen, M, Ulmanen, I 1992The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BgIICytogenet Cell Genet59253257PubMedGoogle Scholar
  10. 10.
    Scanlon, PD, Raymond, FA, Weinshilboum, RM 1979Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activityScience2036365PubMedGoogle Scholar
  11. 11.
    Lotta, T, Vidgren, J, Tilgmann, C, Ulmanen, I, Melen, K, Julkunen, I, Taskinen, J 1995Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzymeBiochemistry3442024210PubMedGoogle Scholar
  12. 12.
    Mannisto, PT, Kaakkola, S 1999Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitorsPharmacol Rev51593628PubMedGoogle Scholar
  13. 13.
    Mosekilde, L, Hermann, AP, Beck-Nielsen, H, Charles, P, Nielsen, SP, Sorensen, OH 1999The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal womenMaturitas31207219CrossRefPubMedGoogle Scholar
  14. 14.
    Abrahamsen, B, Gram, J, Hansen, TB, Beck-Nielsen, H 1995Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurementsBone16385390CrossRefPubMedGoogle Scholar
  15. 15.
    Katzman, DK, Bachrach, LK, Carter, DR, Marcus, R 1991Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girlsJ Clin Endocrinol Metab7313321339PubMedGoogle Scholar
  16. 16.
    Lund, B, Sorensen, OH 1979Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in the Danish populationScand J Clin Lab Invest392330PubMedGoogle Scholar
  17. 17.
    Brixen, K, Nielsen, HK, Eriksen, EF, Charles, P, Mosekilde, L 1989Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-proteinCalcif Tissue Int449398PubMedGoogle Scholar
  18. 18.
    Feigelson, HS, Coetzee, GA, Kolonel, LN, Ross, RK, Henderson, BE 1997A polymorphism in the CYP17 gene increases the risk of breast cancerCancer Res5710631065PubMedGoogle Scholar
  19. 19.
    Thompson, PA, Shields, PG, Freudenheim, JL, Stone, A, Vena, JE, Marshall, JR, Graham, S, Laughlin, R, Nemoto, T, Kadlubar, FF, Ambrosone, CB 1998Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer riskCancer Res5821072110PubMedGoogle Scholar
  20. 20.
    Tofteng, CL, Jensen, JE, Abrahamsen, B, Odum, L, Brot, C 2002Two polymorphisms in the vitamin D receptor gene—association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention StudyJ Bone Miner Res1715351544PubMedGoogle Scholar
  21. 21.
    Somner, J, McLellan, S, Cheung, J, Mak, YT, Frost, M, Knapp, K, Wierzbicki, A, Fogelman, I, Ralston, SH, Hampson, G 2003Polymorphisms in the P450 c17 (17-Hydroxylase/17,20-Lyase) and P450 c19 (Aromatase) genes: association with serum steroid concentrations and bone mineral density in postmenopausal womenCalcif Tissue Int72267Google Scholar
  22. 22.
    Oz, OK, Zerwekh, JE, Fisher, C, Graves, K, Nanu, L, Millsaps, R, Simpson, ER 2000Bone has a sexually dimorphic response to aromatase deficiencyJ Bone Miner Res15507514PubMedGoogle Scholar
  23. 23.
    Feigelson, HS, Sharnes, LS, Pike, MC, Coetzee, GA, Stanczyk, FZ, Henderson, BE 1998Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrationsCancer Res58585587PubMedGoogle Scholar
  24. 24.
    Haiman, CA, Stampfer, MJ, Giovannucci, E, Ma, J, Decalo, NE, Kantoff, PW, Hunter, DJ 2001The relationship between a polymorphism in CYPI7 with plasma hormone levels and prostate cancerCancer Epidemiol Biomarkers Prev10743748PubMedGoogle Scholar
  25. 25.
    Haiman, CA, Hankinson, SE, Colditz, GA, Hunter, DJ, De, VI 2001A polymorphism in CYP17 and endometrial cancer riskCancer Res6139553960PubMedGoogle Scholar
  26. 26.
    Berstein, LM, Imyanitov, EN, Gamajunova, VB, Kovalevskij, AJ, Kuligina, ES, Belogubova, EV, Buslov, KG, Karpova, MB, Togo, AV, Volkov, ON, Kovalenko, IG 2002CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?Cancer Lett1804753CrossRefPubMedGoogle Scholar
  27. 27.
    Burger, HG 1999The endocrinology of the menopauseJ Steroid Biochem Mol Biol693135CrossRefPubMedGoogle Scholar
  28. 28.
    Huang, CS, Chern, HD, Chang, KJ, Cheng, CW, Hsu, SM, Shen, CY 1999Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibilityCancer Res5948704875PubMedGoogle Scholar
  29. 29.
    Ye, Z, Parry, JM 2002The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysisMutagenesis17119126CrossRefPubMedGoogle Scholar
  30. 30.
    Yamada, Y, Watanabe, M, Murata, M, Yamanaka, M, Kubota, Y, Ito, H, Katoh, T, Kawamura, J, Yatani, R, Shiraishi, T 2001Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese populationInt J Cancer92683686CrossRefPubMedGoogle Scholar
  31. 31.
    Wadelius, M, Andersson, AO, Johansson, JE, Wadelius, C, Rane, E 1999Prostate cancer associated with CYP17 genotypePharmacogenetics9635639PubMedGoogle Scholar
  32. 32.
    Habuchi, T, Liqing, Z, Suzuki, T, Sasaki, R, Tsuchiya, N, Tachiki, H, Shimoda, N, Satoh, S, Sato, K, Kakehi, Y, Kamoto, T, Ogawa, O, Kato, T 2000Increased risk of prostate cancer and benign prostatic hynerplasia associated with a CYP17 gene polymorphism with a gene dosage effectCancer Res6057105713PubMedGoogle Scholar
  33. 33.
    Di Blasio, AM, Voutilainen, R, Jaffe, RB, Miller, WL 1987Hormonal regulation of messenger ribonucleic acids for P450scc (cholesterol side-chain cleavage enzyme) and P450c17(17 alpha-hydroxylase/17,20-lyase) in cultured human fetal adrenal cellsJ Clin Endocrinol Metab65170175PubMedGoogle Scholar
  34. 34.
    Barrett-Connor, E, Kritz-Silverstein, D 1996Does hyperinsulinemia preserve bone?Diabetes Care1913881392PubMedGoogle Scholar
  35. 35.
    Biason-Lauber, A, Zachmann, M, Schoenle, EJ 2000Effect of leptin on CYP17 enzymatic activities in human adrenal cells: new insight in the onset of adrenarcheEndocrinology1414461454CrossRefGoogle Scholar
  36. 36.
    Westerlind, KC, Gibson, KJ, Malone, P, Evans, GL, Turner, RT 1998Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized ratsJ Bone Miner Res1310231031PubMedGoogle Scholar
  37. 37.
    Leelawattana, R, Ziambaras, K, Roodman-Weiss, J, Lyss, C, Wagner, D, Klug, T, Armamento-Villareal, R, Civitelli, R 2000The oxidative metabolism of estradiol conditions, postmenopausal bone density, and bone lossJ Bone Miner Res1525132520PubMedGoogle Scholar
  38. 38.
    Yager, JD, Liehr, JG 1996Molecular mechanisms of estrogen carcinogenesisAnnu Rev Pharmacol Toxicol36203232CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • C. L. Tofteng
    • 1
  • B. Abrahamsen
    • 2
  • J. E. B. Jensen
    • 1
  • S. Petersen
    • 1
  • J. Teilmann
    • 1
  • A. Kindmark
    • 3
  • P. Vestergaard
    • 4
  • J. Gram
    • 2
  • B. L. Langdahl
    • 4
  • L. Mosekilde
    • 4
  1. 1.Osteoporosis Research ClinicHvidovre University HospitalHvidovreDenmark
  2. 2.Department of EndocrinologyOdense University HospitalOdenseDenmark
  3. 3.Department of Medical SciencesUppsala University HospitalUppsalaSweden
  4. 4.Department of EndocrinologyAarhus University HospitalAarhusDenmark

Personalised recommendations